This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oragenics, Inc. develops, markets, and sells oral probiotics products and antibiotics for humans and companion pets.View OGEN key stats
Oragenics Inc - OGEN - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Oragenics Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate ORAGENICS INC (OGEN) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity and generally high debt management risk.